FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective Pan-FGFR inhibitor

Cancer Discovery

Volumn 2, Issue 12, 2012, Pages 1118-1133

  Guagnano, Vito ^a   Kauffmann, Audrey ^a   Wöhrle, Simon ^a   Stamm, Christelle ^a   Ito, Moriko ^a   Barys, Louise ^a   Pornon, Astrid ^a   Yao, Yao ^c   Li, Fang ^b   Zhang, Yun ^c   Chen, Zhi ^c   Wilson, Christopher J ^b   Bordas, Vincent ^a   Le Douget, Mickaël ^a   Alex Gaither, L ^b   Borawski, Jason ^b   Monahan, John E ^b   Venkatesan, Kavitha ^b   Brümmendorf, Thomas ^a   Thomas, David M ^d   Garcia Echeverria, Carlos ^a,e   Hofmann, Francesco ^a   Sellers, William R ^b   Graus Porta, Diana ^a   more..

^a NOVARTIS PHARMA AG   (Switzerland)

^b NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^c Novartis Institutes for Biomedical Research   (China)

^d PETER MACCALLUM CANCER CENTRE   (Australia)

^e SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; FIBROBLAST GROWTH FACTOR RECEPTOR; MESSENGER RNA; NVP BGJ 398; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CELL VIABILITY; CHEMOSENSITIVITY; COLON CANCER; CONTROLLED STUDY; DRUG RESPONSE; DRUG SENSITIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE AMPLIFICATION; GENE MUTATION; GENE NUMBER; HUMAN; HUMAN CELL; LIVER CANCER; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OSTEOSARCOMA; STOMACH CANCER; TUMOR VOLUME; TUMOR XENOGRAFT; WESTERN BLOTTING;

ANIMALS; CELL LINE, TUMOR; GENE AMPLIFICATION; HEK293 CELLS; HUMANS; LIVER NEOPLASMS; MICE; MODELS, MOLECULAR; NEOPLASMS; PHENYLUREA COMPOUNDS; PROTEIN KINASE INHIBITORS; PYRIMIDINES; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 1; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 2; RECEPTORS, FIBROBLAST GROWTH FACTOR; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84871491773     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-12-0210     Document Type: Article

References (40)

1. Itoh N. The Fgf families in humans, mice, and zebrafish: their evolutional processes and roles in development, metabolism, and disease. Biol Pharm Bull 2007; 30: 1819-25.
2. Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J, et al. The landscape of somatic copy-number alteration across human cancers. Nature 2010; 463: 899-905.
3. Elbauomy ES, Green AR, Lambros MB, Turner NC, Grainge MJ, Powe D, et al. FGFR1 amplification in breast carcinomas: a chromogenic in situ hybridisation analysis. Breast Cancer Res 2007; 9: R23.
4. Ramos AH, Dutt A, Mermel C, Perner S, Cho J, Lafargue CJ, et al. Amplification of chromosomal segment 4q12 in non-small cell lung cancer. Cancer Biol Ther 2009; 8: 2042-50.
5. Weiss J, Sos ML, Seidel D, Peifer M, Zander T, Heuckmann JM, et al. Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med 2010; 2: 62ra93.
6. Turner N, Lambros MB, Horlings HM, Pearson A, Sharpe R, Natrajan R, et al. Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets. Oncogene 2010; 29: 2013-23.
7. Heiskanen M, Kononen J, Barlund M, Torhorst J, Sauter G, Kallioniemi A, et al. CGH, cDNA and tissue microarray analyses implicate FGFR2 amplification in a small subset of breast tumors. Anal Cell Pathol 2001; 22: 229-34.
8. Hara T, Ooi A, Kobayashi M, Mai M, Yanagihara K, Nakanishi I. Amplification of c-myc, K-sam, and c-met in gastric cancers: detection by fluorescence in situ hybridization. Lab Invest 1998; 78: 1143-53.
9. Mor O, Ranzani GN, Ravia Y, Rotman G, Gutman M, Manor A, et al. DNA amplification in human gastric carcinomas. Cancer Genet Cytogenet 1993; 65: 111-4.
10. Nakatani H, Sakamoto H, Yoshida T, Yokota J, Tahara E, Sugimura T, et al. Isolation of an amplified DNA sequence in stomach cancer. Jpn J Cancer Res 1990; 81: 707-10.
11. Yoshida T, Sakamoto H, Terada M. Amplified genes in cancer in upper digestive tract. Semin Cancer Biol 1993; 4: 33-40.
12. Sawey ET, Chanrion M, Cai C, Wu G, Zhang J, Zender L, et al. Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by oncogenomic screening. Cancer Cell 2011; 19: 347-58.
13. Wilkie AO. Bad bones, absent smell, selfish testes: the pleiotropic consequences of human FGF receptor mutations. Cytokine Growth Factor Rev 2005; 16: 187-203.
14. Greenman C, Stephens P, Smith R, Dalgliesh GL, Hunter C, Bignell G, et al. Patterns of somatic mutation in human cancer genomes. Nature 2007; 446: 153-8.
15. Davies H, Hunter C, Smith R, Stephens P, Greenman C, Bignell G, et al. Somatic mutations of the protein kinase gene family in human lung cancer. Cancer Res 2005; 65: 7591-5.
16. Rand V, Huang J, Stockwell T, Ferriera S, Buzko O, Levy S, et al. Sequence survey of receptor tyrosine kinases reveals mutations in glioblastomas. Proc Natl Acad Sci U S A 2005; 102: 14344-9.
17. Dutt A, Salvesen HB, Chen TH, Ramos AH, Onofrio RC, Hatton C, et al. Drug-sensitive FGFR2 mutations in endometrial carcinoma. Proc Natl Acad Sci U S A 2008; 105: 8713-7.
18. Jang JH, Shin KH, Park JG. Mutations in fibroblast growth factor receptor 2 and fibroblast growth factor receptor 3 genes associated with human gastric and colorectal cancers. Cancer Res 2001; 61: 3541-3.
19. Pollock PM, Gartside MG, Dejeza LC, Powell MA, Mallon MA, Davies H, et al. Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes. Oncogene 2007; 26: 7158-62.
20. Cappellen D, De Oliveira C, Ricol D, de Medina S, Bourdin J, S astre-Garau X, et al. Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat Genet 1999; 23: 18-20.
21. Chesi M, Nardini E, Brents LA, Schrock E, Ried T, Kuehl WM, et al. Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. Nat Genet 1997; 16: 260-4.
22. Taylor JG, Cheuk AT, Tsang PS, Chung JY, Song YK, Desai K, et al. Identification of FGFR4-activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted models. J Clin Invest 2009; 119: 3395-407.
23. Cross NC, Reiter A. Fibroblast growth factor receptor and plateletderived growth factor receptor abnormalities in eosinophilic myeloproliferative disorders. Acta Haematol 2008; 119: 199-206.
24. Maeda T, Yagasaki F, Ishikawa M, Takahashi N, Bessho M. Transforming property of TEL-FGFR3 mediated through PI3-K in a T-cell lymphoma that subsequently progressed to AML. Blood 2005; 105: 2115-23.
25. Guagnano V, Furet P, Spanka C, Bordas V, Le Douget M, Stamm C, et al. Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamin o]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase. J Med Chem 2011; 54: 7066-83.
26. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, et al. The cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 2012; 483: 603-7.
27. Furet P, Caravatti G, Guagnano V, Lang M, Meyer T, Schoepfer J. Entry into a new class of protein kinase inhibitors by pseudo ring design. Bioorg Med Chem Lett 2008; 18: 897-900.
28. Wesche J, Haglund K, Haugsten EM. Fibroblast growth factors and their receptors in cancer. Biochem J 2011; 437: 199-213.
29. Chase A, Grand FH, Cross NC. Activity of TKI258 against primary cells and cell lines with FGFR1 fusion genes associated with the 8p11 myeloproliferative syndrome. Blood 2007; 110: 3729-34.
30. Ueda T, Sasaki H, Kuwahara Y, Nezu M, Shibuya T, Sakamoto H, et al. Deletion of the carboxyl-terminal exons of K-sam/FGFR2 by short homology-mediated recombination, generating preferential expression of specific messenger RNAs. Cancer Res 1999; 59: 6080-6.
31. Wu AL, Coulter S, Liddle C, Wong A, Eastham-Anderson J, French DM, et al. FGF19 regulates cell proliferation, glucose and bile acid metabolism via FGFR4-dependent and independent pathways. PLoS ONE 2011; 6: e17868.
32. Broad-Novartis Cancer Cell Line Encyclopedia (CCLE). Available from: http://www.broadinstitute.org/ccle.
33. Lin BC, Desnoyers LR. FGF19 and cancer. Adv Exp Med Biol 2012; 728: 183-94.
34. Cao L, Yu Y, Bilke S, Walker RL, Mayeenuddin LH, Azorsa DO, et al. Genome-wide identification of PAX3-FKHR binding sites in rhabdomyosarcoma reveals candidate target genes important for development and cancer. Cancer Res 2010; 70: 6497-508.
35. Wolf J, LoRusso PM, Camidge RD, Perez JM, Tabernero J, Hidalgo M, et al. Abstract LB-122: a phase I dose escalation study of NVPBGJ398, a selective pan FGFR inhibitor in genetically preselected advanced solid tumors [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research. 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr LB-122. doi:1538-7445.AM2012-LB-122.
36. Zhang JH, Chung TD, Oldenburg KR. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen 1999; 4: 67-73.
37. Wiederschain D, Wee S, Chen L, Loo A, Yang G, Huang A, et al. Single-vector inducible lentiviral RNAi system for oncology target validation. Cell Cycle 2009; 8: 498-504.
38. Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008; 455: 1061-8.
39. Mermel CH, Schumacher SE, Hill B, Meyerson ML, Beroukhim R, Getz G. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol 2011; 12: R41.
40. Ito M, Barys L, O'Reilly T, Young S, Gorbatcheva B, Monahan J, et al. Comprehensive mapping of p53 pathway alterations reveals an apparent role for both SNP309 and MDM2 amplification in sarcomagenesis. Clin Cancer Res 2011; 17: 416-26.